Group 1 - The core announcement is that MicroPort Cardiac Rhythm Management (MicroPort) has received a favorable review from the National Medical Products Administration (NMPA) for its new generation implantable cardioverter-defibrillator (ICD) TILEN/EYLEN, which is expected to enter the innovative medical device special review process [1] - TILEN/EYLEN is anticipated to be the first domestically approved MRI-safe ICD with independent intellectual property rights, addressing a significant technological gap in the domestic market [1] - The device features automatic MRI functionality, remote follow-up capabilities using low-power Bluetooth technology, and an industry-leading lifespan, which collectively aim to enhance patient comfort, compliance, and reduce long-term economic burdens [1] Group 2 - Sudden Cardiac Death (SCD) is a major global cause of mortality, and ICDs have been proven to be the most effective preventive measure against SCD, restoring normal heart rhythm during life-threatening arrhythmias [2] - The PLATINIUM series ICD products have already received NMPA approval in September 2024, marking the first domestically approved ICD, thus providing more treatment options for SCD in China and promoting the local development and application of high-energy defibrillator devices [2] - The entry of TILEN/EYLEN into the NMPA green channel is expected to accelerate the domestic production process of MRI-safe ICDs [2]

Core Viewpoint - MicroPort Cardiac Rhythm Management-B (02160) has announced that its next-generation implantable cardioverter-defibrillator (ICD) TILEN/EYLEN is set to enter the NMPA's special review process, potentially becoming the first domestically approved MRI-safe ICD with independent intellectual property rights in China [1][2] Group 1: Product Development - TILEN/EYLEN is a core product of a national key research and development project initiated by the Ministry of Science and Technology, aimed at filling a technological gap in the domestic market [1] - The ICD features automatic MRI functionality, significantly reducing patient discomfort caused by asynchronous modes and simplifying the MRI scanning process [1] - It includes remote follow-up capabilities based on low-power Bluetooth technology, enhancing patient compliance through a complete solution supported by domestic data centers [1] Group 2: Market Impact - Sudden Cardiac Death (SCD) is a leading cause of death globally, and ICDs have been proven to be the most effective measure for preventing SCD by restoring normal heart rhythm during life-threatening arrhythmias [2] - The company's PLATINIUM™ series ICD products received NMPA approval in September 2024, marking the first domestically approved ICD and providing more options for SCD prevention and treatment for Chinese patients [2] - The entry of TILEN/EYLEN into the NMPA green channel is expected to accelerate the domestic production process of MRI-safe ICDs [2]

Group 1 - The National Medical Products Administration (NMPA) has announced the acceptance of the new generation implantable cardioverter-defibrillator (ICD) TILEN/EYLEN for special review, which is expected to be the first domestically approved MRI-safe ICD with independent intellectual property rights [1] - TILEN/EYLEN is a core product of a national key research and development project, aiming to fill the technological gap in the domestic market, featuring advantages such as automatic MRI functionality, remote follow-up capabilities, and industry-leading lifespan [1] - The ICD market is significant as sudden cardiac death (SCD) is a major global cause of death, and ICDs have been proven to be the most effective measure for preventing SCD, providing critical treatment during life-threatening arrhythmias [2] Group 2 - The company's PLATINIUM series ICD products received NMPA approval in September 2024, marking the first domestically approved ICD, thus expanding treatment options for SCD in China and promoting the local development and application of high-energy defibrillator devices [2] - The entry of TILEN/EYLEN into the NMPA green channel is expected to accelerate the domestic production process of MRI-safe ICDs [2]

Group 1 - The core focus of the news is on the developments of the subsidiary, Boling Brain Machine, particularly its B-end product, Cyberlink AM5, which is currently undergoing multi-center clinical trials [1] - If the clinical trials progress smoothly, the company expects to complete the registration application for Class II medical devices by the first half of 2026 [1] - This event may significantly impact the company's technological commercialization process [1]

Group 1 - The core point of the article is that Innovation Medical announced it has provided a total guarantee of 53.2 million yuan to its subsidiaries, which represents 2.99% of the company's most recent audited net assets [2] - The company has stated that all external guarantees are solely for its subsidiaries, with no other external guarantees in place [2] - There are no overdue external guarantees or any guarantees related to litigation matters [2]

Group 1 - The company, Innovation Medical, announced on February 10 that it has provided a total guarantee of 53.2 million yuan for its subsidiaries, which accounts for 2.99% of the company's most recent audited net assets [1]

Core Viewpoint - Innovation Medical announced the convening of its seventh board meeting for 2026 on February 10, 2026, via telecommunication voting, where it reviewed the proposal to provide guarantees for Hongrun Pharmaceutical and other documents [1] Group 1 - The board meeting was held on February 10, 2026, and utilized a telecommunication voting method [1] - The agenda included the review of a proposal to provide guarantees for Hongrun Pharmaceutical [1]

本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 证券代码：002173 证券简称：创新医疗 公告编号：2026-007 创新医疗管理股份有限公司 关于为鸿润医药提供担保的公告 一、本次担保情况概述 创新医疗管理股份有限公司（以下简称"公司"）全资控股子公司浙江鸿润 医药有限公司（以下简称"鸿润医药"）因生产经营需要，拟向北京银行股份有 限公司绍兴诸暨支行（以下简称"北京银行诸暨支行"）在人民币 1,000 万元的 授信额度内申请贷款，贷款期限为一年。公司于 2026 年 2 月 10 日召开的第七届 董事会 2026 年第一次临时会议审议通过了《关于为鸿润医药提供担保的议案》， 同意公司为鸿润医药在 1,000 万元授信额度内向北京银行诸暨支行申请贷款提 供担保。 本次担保总额为人民币 1,000 万元，未超过公司最近一期经审计净资产的 10%；本次董事会审议的担保议案生效后，公司担保总额为 5,320 万元，未超过 公司最近一期经审计净资产的 50%，也未超过公司最近一期经审计总资产的 30%； 最近一期鸿润医药资产负债率未超过 70%。根据《深圳证券交易所 ...

证券代码：002173 证券简称：创新医疗 公告编号：2026-006 创新医疗管理股份有限公司 第七届董事会 2026 年第一次临时会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 创新医疗管理股份有限公司（以下简称"公司"）第七届董事会于 2026 年 2 月 10 日召开了 2026 年第一次临时会议。本次会议以通讯表决方式召开。会议通 知于 2026 年 2 月 6 日以书面形式发出。本次会议由陈海军董事长主持，应出席 董事 9 名，实际出席 9 名。本次会议召开符合《公司法》及公司《章程》的规定， 合法有效。 二、董事会会议审议情况 与会董事就议案进行了审议、表决，以 9 票赞成、0 票反对、0 票弃权的表 决结果一致通过了《关于为鸿润医药提供担保的议案》。 为满足浙江鸿润医药有限公司生产经营需要，有利于保障其业务发展，公司 决定为浙江鸿润医药有限公司在1,000万元授信额度内向北京银行股份有限公司 绍兴诸暨支行申请贷款提供担保。 三、备查文件 公司《第七届董事会 2026 年第一次临时会议决议》。 特此公告。 创 ...

Group 1 - The core viewpoint of the article highlights the increasing investment and research activity in the brain-computer interface (BCI) industry in China, with a focus on key companies and patent trends [1][4][5] Group 2 - The research and development investment in the BCI industry by listed companies in China is steadily increasing from 2020 to 2024, indicating a strengthening of R&D efforts [1] - The number of patent applications in China's BCI industry showed a steady growth trend, peaking at 258 applications in 2021, followed by a decrease to 209 applications in 2024 [4] - Tianjin University is identified as the leading patent applicant in the BCI sector, with a total of 126 related patents, followed by South China University of Technology and Xi'an Jiaotong University with 80 and 78 patents respectively [5][7] - The most popular technology patents in the BCI industry are in the category of electrical digital data processing (G06F), with a total of 1,013 patents, followed by diagnostic and surgical technologies (A61B) with 712 patents, and specific computing models (G06N) with 313 patents [8]